Ondine Biomedical Inc.
OBIMF
$0.11
-$0.02-15.39%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 97.05% | 101.39% | 105.63% | 100.49% | 55.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 97.05% | 101.39% | 105.63% | 100.49% | 55.26% |
| Cost of Revenue | 83.00% | 87.16% | 38.34% | 34.83% | 42.64% |
| Gross Profit | 106.96% | 111.42% | 215.18% | 207.48% | 65.60% |
| SG&A Expenses | -19.02% | -17.25% | -39.82% | -41.33% | -3.02% |
| Depreciation & Amortization | -9.14% | -7.18% | 16.15% | 13.33% | 25.32% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.85% | 3.06% | -29.82% | -31.57% | -7.28% |
| Operating Income | 4.27% | 2.18% | 34.74% | 36.37% | 9.23% |
| Income Before Tax | 3.54% | 1.43% | 39.85% | 41.36% | 12.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.54% | 1.43% | 39.85% | 41.36% | 12.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.54% | 1.43% | 39.85% | 41.36% | 12.40% |
| EBIT | 4.27% | 2.18% | 34.74% | 36.37% | 9.23% |
| EBITDA | 4.02% | 1.92% | 34.99% | 36.62% | 9.31% |
| EPS Basic | 22.52% | 20.67% | 48.04% | 49.77% | 12.72% |
| Normalized Basic EPS | 23.16% | 20.21% | 45.67% | 46.97% | 12.04% |
| EPS Diluted | 22.52% | 20.67% | 48.04% | 49.77% | 12.72% |
| Normalized Diluted EPS | 23.16% | 20.21% | 45.67% | 46.97% | 12.04% |
| Average Basic Shares Outstanding | 24.01% | 24.01% | 16.53% | 16.53% | 0.07% |
| Average Diluted Shares Outstanding | 24.01% | 24.01% | 16.53% | 16.53% | 0.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
